资金流向方面，主力资金净流出2166.85万元，特大单买入1852.71万元，占比7.85%，卖出1752.18万 元，占比7.43%；大单买入5786.00万元，占比24.52%，卖出8053.38万元，占比34.13%。 凯莱英所属申万行业为：医药生物-医疗服务-医疗研发外包。所属概念板块包括：CRO概念、高派息、 H股、融资融券、基金重仓等。 10月9日，凯莱英盘中下跌2.01%，截至10:01，报111.42元/股，成交2.36亿元，换手率0.66%，总市值 401.77亿元。 凯莱英今年以来股价涨48.57%，近5个交易日涨1.99%，近20日涨1.93%，近60日涨26.23%。 今年以来凯莱英已经1次登上龙虎榜，最近一次登上龙虎榜为8月8日，当日龙虎榜净买入-1.80亿元；买 入总计3.83亿元 ，占总成交额比19.59%；卖出总计5.64亿元 ，占总成交额比28.81%。 资料显示，凯莱英医药集团(天津)股份有限公司位于天津经济技术开发区第七大街71号，成立日期1998 年10月7日，上市日期2016年11月18日，公司主营业务涉及提供CMO医药外包服务。主营业务收入构成 为：小分子CDMO解 ...

Core Viewpoint - Kailaiying's stock price has shown significant growth this year, with a year-to-date increase of 49.53%, indicating strong market performance and investor interest [1][2]. Financial Performance - For the first half of 2025, Kailaiying achieved a revenue of 3.188 billion yuan, representing a year-on-year growth of 18.20%, and a net profit attributable to shareholders of 617 million yuan, up 23.71% [2]. - The company has distributed a total of 2.405 billion yuan in dividends since its A-share listing, with 1.701 billion yuan distributed over the past three years [3]. Stock Market Activity - As of September 30, Kailaiying's stock was trading at 112.14 yuan per share, with a market capitalization of 40.437 billion yuan and a trading volume of 585 million yuan [1]. - The stock has seen a net inflow of 8.6225 million yuan from major funds, with significant buying and selling activity from large orders [1]. Shareholder Structure - As of June 30, 2025, Kailaiying had 41,300 shareholders, a decrease of 5.16% from the previous period, with an average of 0 shares per shareholder [2]. - The top shareholders include various funds, with notable changes in holdings among major institutional investors [3].

截至发稿，姚炜累计任职时间6年281天，现任基金资产总规模4.56亿元，任职期间最佳基金回报 65.93%， 任职期间最差基金回报-38.1%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 数据显示，中海基金旗下1只基金重仓凯莱英。中海医药混合A（000878）二季度增持7.39万股，持有股 数22.43万股，占基金净值比例为6.25%，位居第六大重仓股。根据测算，今日浮盈赚取约132.58万元。 中海医药混合A（000878）成立日期2014年12月17日，最新规模2.3亿。今年以来收益29.89%，同类排 名2686/8246；近一年收益41.89%，同类排名3946/8054；成立以来收益135.66%。 中海医药混合A（000878）基金经理为姚炜。 9月15日，凯莱英涨5.27%，截至发稿，报117.99元/股，成交12.45亿元，换手率3.43%，总市值425.46亿 元。 资料显示，凯莱英医药集团(天津)股份有限公司位于天津经济技术开 ...

9月11日，凯莱英跌5.86%，截至发稿，报104.50元/股，成交2.82亿元，换手率0.86%，总市值376.82亿 元。 资料显示，凯莱英医药集团(天津)股份有限公司位于天津经济技术开发区第七大街71号，成立日期1998 年10月7日，上市日期2016年11月18日，公司主营业务涉及提供CMO医药外包服务。主营业务收入构成 为：小分子CDMO解决方案76.19%，新兴服务23.71%，其他0.10%。 从凯莱英十大流通股东角度 数据显示，华宝基金旗下1只基金位居凯莱英十大流通股东。华宝中证医疗ETF（512170）二季度减持 109.21万股，持有股数664.67万股，占流通股的比例为1.93%。根据测算，今日浮亏损失约4320.35万 元。 华宝中证医疗ETF（512170）成立日期2019年5月20日，最新规模261.47亿。今年以来收益19.93%，同 类排名2253/4222；近一年收益43.62%，同类排名2230/3798；成立以来收益17.52%。 华宝中证医疗ETF（512170）基金经理为胡洁。 截至发稿，胡洁累计任职时间12年334天，现任基金资产总规模843.4亿元，任职期间最佳基 ...

Core Viewpoint - Kailaiying's stock price has shown significant fluctuations, with a year-to-date increase of 40.92% and a recent decline over the past 20 days, indicating potential volatility in the market [1][2]. Financial Performance - For the first half of 2025, Kailaiying achieved a revenue of 3.188 billion yuan, representing a year-on-year growth of 18.20%, while the net profit attributable to shareholders was 617 million yuan, up 23.71% [2]. - The company has distributed a total of 2.405 billion yuan in dividends since its A-share listing, with 1.701 billion yuan distributed over the past three years [3]. Stock Market Activity - As of August 29, Kailaiying's stock price was 105.68 yuan per share, with a market capitalization of 38.108 billion yuan and a trading volume of 391 million yuan [1]. - The stock has seen a net inflow of 9.1262 million yuan from main funds, with significant buying and selling activity noted in large orders [1]. Shareholder Structure - As of June 30, 2025, Kailaiying had 41,300 shareholders, a decrease of 5.16% from the previous period, with no circulating shares per shareholder [2][3]. - Major shareholders include China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited, with varying changes in their holdings [3].